№ files_lp_4_process_3_087873
File format: docx
Character count: 340
File size: 19 KB
Collection of supplementary figures illustrating T cell fluctuations, marker expression, and microbiome sequencing results during chemoradiotherapy and subsequent nivolumab therapy.
Year:
2026
Study type:
Immunology / Oncology
Document type:
Supplementary material
Institution:
Research laboratory or medical center
Methods:
Flow cytometry, 16S rRNA sequencing
Subjects:
Tumor-infiltrating lymphocytes and peripheral blood mononuclear cells
Treatment:
Chemoradiotherapy followed by nivolumab
Markers analyzed:
CD8+, CD4+, Ki-67, CTLA-4
Sample type:
Tumor tissue and stool
Period of study:
Pre- and post-chemoradiotherapy
Audience:
Scientific community
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2013
Region / City:
United Kingdom
Subject:
Oncology, Clinical Trial Data
Document Type:
Clinical Trial Data Summary
Organization / Institution:
Oxford University
Authors:
Michael Youdell, Andrew Blake
Target Audience:
Researchers and clinicians in oncology
Study Period:
Phase 2/3 trial conducted before 2013
Trial Registration:
SCOPE1
Data Included:
Clinical, demographic, RNA sequencing, treatment outcomes
Treatment Groups:
Chemoradiotherapy alone, Chemoradiotherapy plus cetuximab
Patient Population:
Non-metastatic oesophageal carcinoma, stage I–III, WHO 0–1
Sample Size:
258 patients
Primary Endpoints:
Treatment failure-free proportion at week 24, overall survival
Data Quality Control:
MultiQC v1.14, nf-core/rnaseq pipeline
Year:
2023
Region / City:
Australia
Topic:
Oncology, Urothelial carcinoma, Immunotherapy
Document type:
Medical submission
Organization / Institution:
Bristol-Myers Squibb Australia Pty Ltd
Author:
Unknown
Target audience:
Medical practitioners, healthcare professionals
Period of validity:
Ongoing
Approval date:
2023
Date of amendments:
N/A
Source:
TGA/PBAC Parallel Process
Indication:
First-line treatment for unresectable or metastatic urothelial carcinoma
Treatment phase:
Initial and Continuing treatment
Condition:
Unresectable or metastatic urothelial carcinoma
Treatment criteria:
Patient must meet specific clinical and therapeutic criteria
Year:
2024
Region / City:
Australia
Subject:
Nivolumab and ipilimumab treatment for unresectable malignant mesothelioma
Document type:
Submission report
Organ / Institution:
PBAC, DUSC, TGA
Author:
Unknown
Target audience:
Pharmaceutical regulators, healthcare professionals
Period of validity:
2021-2024
Approval date:
July 2021
Date of changes:
March 2024
Year:
2022
Region / City:
Australia
Theme:
Oncology, Medical Treatment
Document Type:
Pharmaceutical Submission
Organization / Institution:
Bristol-Myers Squibb Australia Pty Ltd
Author:
Not specified
Target Audience:
Medical professionals, Oncologists
Period of validity:
Ongoing
Approval Date:
4 July 2018
Date of Changes:
Not specified
Note:
Contextual Description
Year:
2021
Region / city:
Australia
Theme:
Cancer treatment
Document type:
Submission for Authority Required listing
Organization / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Bristol-Myers Squibb Australia Pty Ltd
Target audience:
Medical practitioners
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2023
Region / City:
Australia
Subject:
Cancer Treatment / Immunotherapy
Document Type:
Submission
Organ / Institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Bristol-Myers Squibb
Target Audience:
Medical professionals, healthcare policy makers, pharmaceutical industry stakeholders
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2019
Region / city:
Australia
Theme:
Oncology, Chemotherapy
Document type:
Resubmission for PBS listing
Organ / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Bristol-Myers Squibb Australia Pty Ltd
Target audience:
Medical professionals, PBAC members
Validity period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Year:
2019
Region / city:
Australia
Topic:
Adjuvant melanoma treatment
Document type:
Public Summary Document
Organization / institution:
PBAC
Author:
PBAC
Target audience:
Healthcare professionals
Period of validity:
Not specified
Approval date:
July 2019
Date of changes:
July 2019
Year:
2025
Region / Country:
United States
Subject:
Oncology / Immunotherapy
Document Type:
Patient Educational Material
Organization:
National Cancer Institute (NCI)
Intended Audience:
Research staff, clinical trial participants
Version Date:
December 5, 2025
Drug Names:
Nivolumab, Relatlimab (Opdualag)
Side Effect Categories:
Common, Occasional, Rare
Clinical Trial Networks:
CTEP-supported US sites
Regulatory Note:
Not approved by NCI CIRB as patient information sheet for trials
Version:
10.31.2111.13
Release Date:
2024-11-01
Module:
Dynamics 365 FO TMS
Enhancement:
Loan List Page Performance Improvement, Features Tab for Treasury Parameters
Software Version:
Microsoft Dynamics 365 for Finance and Operations 10.0.41
Note:
Context
Year:
2011
Region / City:
Global
Topic:
Accounts Receivable Management
Document Type:
Technical Documentation
Organization / Institution:
Microsoft Corporation
Author:
Microsoft Dynamics Team
Target Audience:
Financial Professionals, Accountants, System Administrators
Effective Date:
2011
Modification Date:
Not specified
Year:
2011
Region / City:
Global
Subject:
Product Configuration, Microsoft Dynamics AX 2012
Document Type:
Concept Paper
Author:
Microsoft
Target Audience:
Application Developers, Implementers
Period of Validity:
N/A
Approval Date:
August 2011
Modification Date:
N/A
Contextual Description:
This document outlines the product configuration technology options available in Microsoft Dynamics AX 2012 for configuring product masters and creating product variants.
Year:
2011
Organization:
Microsoft
Product:
Microsoft Dynamics AX 2012
Document type:
Concept Paper
Topic:
Travel and Expense Policies
Target audience:
Users and administrators of Microsoft Dynamics AX 2012
URL:
http://www.microsoft.com/dynamics/ax
Effective period:
August 2011
Year:
2011
Note:
Region / City
Topic:
Data import and update
Document Type:
Concept Paper
Keywords:
Microsoft Dynamics, Excel Add-in, Data import, Dynamics AX
Context:
Concept Paper outlining the use of the Excel Add-in for updating and importing data into Microsoft Dynamics AX 2012.
Year:
2011
Region / city:
Global
Topic:
Business process automation
Document type:
Technical guide
Organization / institution:
Microsoft
Author:
Microsoft
Target audience:
Business analysts, IT professionals, developers, companies using Microsoft Dynamics AX 2012
Period of validity:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2011
Region / City:
Worldwide
Theme:
Financial Management
Document Type:
Product Documentation
Organization / Institution:
Microsoft Corporation
Author:
Microsoft Corporation
Target Audience:
Financial Professionals, Treasury Staff
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Context Description:
A product documentation source outlining the cash and bank management features of Microsoft Dynamics AX 2012 for financial professionals, focusing on payment handling, reconciliation, and role centers for treasury staff.
Year:
2011
Software:
Microsoft Dynamics AX 2012
Document type:
Concept Paper
Subject:
Inventory management, transaction statuses
Audience:
Internal users of Microsoft Dynamics AX
Document ID:
CCAX2012DI0008
Date:
August 2011
Scope:
Description of StatusIssue and StatusReceipt statuses, impact on inventory, and system architecture
Year:
2011
Region / City:
Global
Topic:
Sales Order Management
Document Type:
Technical Documentation
Organization / Institution:
Microsoft Corporation
Author:
Microsoft
Target Audience:
Organizations using Microsoft Dynamics AX 2012
Effective Period:
Ongoing
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2011
Region / City:
Global
Topic:
Quality Management, Supply Chain
Document Type:
Technical Documentation
Organization / Institution:
Microsoft Corporation
Author:
Microsoft
Target Audience:
Business professionals, IT specialists
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
N/A
Subject:
Dynamics 365, Order Management, Implementation
Document Type:
Guide
Organization / Institution:
Microsoft
Author:
Ray Bennett
Target Audience:
Professionals implementing Dynamics 365 Intelligent Order Management
Effective Period:
N/A
Approval Date:
N/A
Modification Date:
1/31/2023